Loading...

Biofrontera Inc.

BFRINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.07
$0.01(0.94%)

Biofrontera Inc. (BFRI) Company Profile & Overview

Explore Biofrontera Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Biofrontera Inc. (BFRI) Company Profile & Overview

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOHermann Luebbert

Contact Information

781 245 1325
120 Presidential Way, Woburn, MA, 01801

Company Facts

92 Employees
IPO DateOct 29, 2021
CountryUS
Actively Trading

Frequently Asked Questions

;